S Gastrointestinal And Liver Disease 12th Edition Hot [updated] -

The biggest name change in hepatology history is covered in depth. The term NAFLD is out; is in. The 12th edition is the first major textbook to fully integrate the new nomenclature and the revised treatment pathways involving GLP-1 agonists (like semaglutide) specifically for liver fibrosis.

The 12th Edition was officially published in . It is currently available at several major retailers: Amazon India : ₹20,750 DNAMART : ₹20,999 Elsevier Health : Directly from the publisher

In-depth coverage of novel agents.

Pathophysiology, Diagnosis, Management * Editors: Raymond T. Chung, David T. Rubin, Mel Wilcox. Published: December 10, 2025. s gastrointestinal and liver disease 12th edition hot

12th edition Sleisenger and Fordtran's Gastrointestinal and Liver Disease released in December 2025

: Clinical instructions on complex balloon dilatation, therapeutic stent placement, and targeted management of vascular lesions like small bowel angioectasia.

A quick overview of the physical and digital footprint of this essential publication shows its massive scale: Specification The biggest name change in hepatology history is

: Use the formatted flowcharts immediately when evaluating ambiguous presentations like acute abdominal pain or occult gastrointestinal bleeding.

Disclaimer: This post is for informational purposes and is an endorsement of the textbook’s educational value.

Sleisenger and Fordtran's Gastrointestinal and Liver Disease The 12th Edition was officially published in

The pharmacology section has been updated to cover targeted treatments for Inflammatory Bowel Disease (IBD), including Crohn's disease and ulcerative colitis. It features detailed therapeutic data on: Anti-integrin therapies. Interleukin (IL-23) inhibitors.

| Editor | Primary Affiliation | Role & Expertise | | :--- | :--- | :--- | | | Massachusetts General Hospital, Harvard Medical School | Director of Hepatology and the Liver Center; a leading authority on viral hepatitis and liver disease. | | David T. Rubin, MD | University of Chicago Medicine | Chief of the Section of Gastroenterology, Hepatology & Nutrition; a globally recognized expert in Inflammatory Bowel Disease (IBD). | | C. Mel Wilcox, MD | University of Alabama at Birmingham (UAB) | Director of the Division of Gastroenterology and Hepatology; renowned for expertise in pancreatic disease and endoscopic ultrasound. |

For medical libraries and practicing physicians deciding whether to upgrade their reference material, the technical improvements are clear: